These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
397 related items for PubMed ID: 27565910
1. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F. Lung Cancer; 2016 Sep; 99():31-7. PubMed ID: 27565910 [Abstract] [Full Text] [Related]
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA. Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332 [Abstract] [Full Text] [Related]
3. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE. Clin Cancer Res; 2012 Aug 15; 18(16):4406-14. PubMed ID: 22733536 [Abstract] [Full Text] [Related]
4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K. Jpn J Clin Oncol; 2012 Jun 15; 42(6):528-33. PubMed ID: 22457323 [Abstract] [Full Text] [Related]
5. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Oh IJ, Ban HJ, Kim KS, Kim YC. Lung Cancer; 2012 Jul 15; 77(1):121-7. PubMed ID: 22333554 [Abstract] [Full Text] [Related]
6. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T. Ann Oncol; 2015 May 15; 26(5):888-894. PubMed ID: 25669832 [Abstract] [Full Text] [Related]
7. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. J Clin Oncol; 2011 Jul 20; 29(21):2866-74. PubMed ID: 21670455 [Abstract] [Full Text] [Related]
8. [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?]. Tang C, Li X, Guo W, Li J, Qin H, Wang W, Qu L, An J, Gao H, Liu X. Zhongguo Fei Ai Za Zhi; 2013 Jul 20; 16(7):345-52. PubMed ID: 23866664 [Abstract] [Full Text] [Related]
9. A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. Nishino K, Imamura F, Morita S, Mori M, Komuta K, Kijima T, Namba Y, Kumagai T, Yamamoto S, Tachibana I, Nakazawa Y, Uchida J, Minami S, Takahashi R, Yano Y, Okuyama T, Kumanogoh A. Lung Cancer; 2013 Nov 20; 82(2):299-304. PubMed ID: 24018023 [Abstract] [Full Text] [Related]
10. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Hirose T, Fujita K, Kusumoto S, Oki Y, Murata Y, Sugiyama T, Ishida H, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ohmori T, Sasaki Y. Lung Cancer; 2016 Mar 20; 93():69-76. PubMed ID: 26898617 [Abstract] [Full Text] [Related]
11. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, Fukuoka M. Lung Cancer; 2017 Feb 20; 104():119-125. PubMed ID: 28212993 [Abstract] [Full Text] [Related]
12. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]. Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X. Zhongguo Fei Ai Za Zhi; 2012 May 20; 15(5):299-304. PubMed ID: 22613337 [Abstract] [Full Text] [Related]
13. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer. Horiike A, Yamamoto N, Tanaka H, Yanagitani N, Kudo K, Ohyanagi F, Ono A, Naito T, Murakami H, Horai T, Nishio M. Anticancer Res; 2014 Apr 20; 34(4):1975-81. PubMed ID: 24692734 [Abstract] [Full Text] [Related]
14. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. J Clin Oncol; 2016 Sep 20; 34(27):3258-66. PubMed ID: 27507876 [Abstract] [Full Text] [Related]
15. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ. Lung Cancer; 2012 Jan 20; 75(1):82-8. PubMed ID: 21684626 [Abstract] [Full Text] [Related]
16. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N. Cancer Chemother Pharmacol; 2015 Oct 20; 76(4):835-41. PubMed ID: 26349474 [Abstract] [Full Text] [Related]
17. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Ichihara E, Hotta K, Takigawa N, Kudo K, Kato Y, Honda Y, Hayakawa H, Minami D, Sato A, Tabata M, Tanimoto M, Kiura K. Lung Cancer; 2013 Sep 20; 81(3):435-439. PubMed ID: 23809059 [Abstract] [Full Text] [Related]
18. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Lancet Oncol; 2015 Aug 20; 16(8):990-8. PubMed ID: 26159065 [Abstract] [Full Text] [Related]
19. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, Zhou YS, Liao GY, Li QP, Xiao SJ, Cai JZ. Trials; 2015 Apr 10; 16():146. PubMed ID: 25873045 [Abstract] [Full Text] [Related]
20. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. Yang CJ, Hung JY, Tsai MJ, Wu KL, Liu TC, Chou SH, Lee JY, Hsu JS, Huang MS, Chong IW. BMC Pharmacol Toxicol; 2017 May 10; 18(1):21. PubMed ID: 28486985 [Abstract] [Full Text] [Related] Page: [Next] [New Search]